NCT04645147View on ClinicalTrials.gov

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2026

Conditions
EBVEpstein-Barr Virus InfectionInfectious Mononucleosis
Interventions
BIOLOGICAL

EBV gp350-Ferritin Vaccine

A 50 micrograms dose of EBV gp350-Ferritin vaccine will be administered intramuscularly for each vaccination at Days 0, 30, and 180 to all participants.

OTHER

Matrix-M1

Each vaccine dose will consist of 50 micrograms of EBV gp350-Ferritin combined with 49 micrograms of Matrix-M1.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH